Patent · US Active

Human PD-L1 antibodies

US11208486B2 · kind B2 · utility

0Cited by

0References

18Claims

0Family size

Assignee

I-MAB BIOPHARMA US LIMITED · US

Inventors

Lei Fang · Katy, US
Yuanyuan Yang · Baltimore, US
Zhengyi Wang · Shanghai, CN
Bingshi Guo · Shanghai, CN
Feifei Cui · Shanghai, CN

Key dates

Filing date	Apr 26, 2020
Grant date	Dec 28, 2021
Priority date	—
Expiry date	Apr 26, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are full human anti-PD-L1 antibodies or fragments thereof. In various examples, the antibodies or fragments thereof include a VH CDR1, a VH CDR2, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3 which are selected from sequence groups of SEQ ID NO: 35-42, SEQ ID NO: 43-51, SEQ ID NO: 52-66, SEQ ID NO: 67-79, SEQ ID NO:80-88 and SEQ ID NO: 89-102, respectively, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.